Search
for
Sort by
Research 91–120 of 788
- A novel therapeutic paradigm for patients with extensive alopecia areata
- Harnessing neuroendocrine controls of keratin expression: A new therapeutic strategy for skin diseases?
- New drugs under investigation for the treatment of alopecias
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- Hidradenitis Suppurativa and Comorbid Disorder Biomarkers, Druggable Genes, New Drugs and Drug Repurposing—A Molecular Meta-Analysis
- Combination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study
- N6-methyladenosine (m6A)-circHECA from secondary hair follicle of cashmere goats: identification, regulatory network and expression regulated potentially by methylation of its host gene promoter
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- An urticarial drug eruption caused by tofacitinib for alopecia universalis
- The role of janus kinases in the treatment of autoimmune skin diseases
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
- Precision therapeutics in non-scarring alopecia: a systemic genomic and pathway-based framework for targeted interventions
- Microarray Gene Expression Analysis of Lesional Skin in Canine Pemphigus Foliaceus
- TNC+ fibroblasts involve in skin inflammation via neuro-immune and interacting with T cells
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
- Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
- Tissue Retinol‐Binding Protein 4 Expression and Its Genetic Variants (rs3758539) in Patients With Severe and Treatment‐Refractory Alopecia Areata: Association With Response to Baricitinib
- Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry about?
- An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
- At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
- A Bibliometric Analysis of Alopecia Areata Literature over the Past 50 Years.
- Pharmacological Treatment of Alopecia
- Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn’s disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient
- Alopecia areata
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- Sterol Intermediates of Cholesterol Biosynthesis Inhibit Hair Growth and Trigger an Innate Immune Response in Cicatricial Alopecia